Latest Articles

Publication Date
Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.

Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …

Published: Sept. 24, 2026, midnight
A novel approach to treating Endometriosis-Related Repeated IVF failures- insights from single case report.

This report explores the case of a young, normal-responder nulligravida with peritoneal endometriosis and recurrent implantation failure, with poor embryo quality during multiple failed attempts at IVF treatment. The patient …

Published: Sept. 24, 2026, midnight
CHRONIC OVERLAPPING PAIN CONDITIONS IN REFRACTORY UROLOGIC CHRONIC PELVIC PAIN SYNDROME (UCPPS):COMORBIDITY PATTERNS, ILLNESS BURDEN, AND TREATMENT IMPLICATIONS.

To examine Chronic Overlapping Pain Conditions (COPC) prevalence in Urologic Chronic Pelvic Pain Syndrome (UCPPS) patients and assess the independent contributions of specific COPCs and pairwise COPC combinations to severity …

Published: Sept. 21, 2026, midnight
Ovarian Precancerous Lesions and Their Molecular Landscape: A Structured Scoping Review Focused on STIC and Related Precursors of Epithelial Ovarian Cancer.

Ovarian cancer remains one of the deadliest gynecologic malignancies because of late-stage diagnosis, biological heterogeneity, and the lack of effective early detection strategies. Epithelial ovarian cancer (EOC) comprises several histotypes, …

Published: Sept. 18, 2026, midnight
Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances.

Background: Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic …

Published: Sept. 17, 2026, midnight
Phytochemicals Modulating Receptor Tyrosine Kinase Signaling Networks in Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory condition that is marked by the growth of lesions outside the uterus, along with angiogenesis, fibrosis, immune dysregulation, and pain sensitization. There is now …

Published: Sept. 7, 2026, midnight
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Immune Suppression and Somatic Mutation in Endometriosis - An Opportunity for Personalized Immunotherapy.

Endometriosis is a chronic, inflammatory condition affecting around 10% of reproductive-age women, characterized by the presence of endometrial-like tissue outside of the uterus. The effects of endometriosis include chronic pelvic …

Published: Aug. 14, 2026, midnight
When It's Not Just "That Time of the Month": Identifying Thoracic Endometriosis in the Context of Recurrent Pleural Effusion.

Recurrent hemorrhagic pleural effusion presents as a challenge for both the clinician and the patient, with common causes being tuberculosis, malignancy, and collagen vascular diseases. Among uncommon causes of recurrent …

Published: Aug. 4, 2026, midnight
Stepwise laparoscopic uterine artery ligation using pararectal and paravesical retroperitoneal approaches.

Mastering the paravesical and pararectal spaces facilitates the vascular control within the pelvis. A single method or a combination of surgical techniques, pararectal or paravesical approach, can be employed depending …

Published: July 29, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!